Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Ono & Congruence Partner on Oncology Small Molecule Corrector Discovery
Details : Under the agreement, Congruence will use its Revenir platform to develop small-molecule correctors targeting cancers. Ono has secured an exclusive global option for development and commercialization.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Congruence, Ono Collaborate on Cancer Small Molecule Correctors Development
Details : The collaboration aims to discover novel small molecule drug candidates leveraging Congruence's proprietary drug discovery platform, Revenir, for the treatment of cancer.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration